Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel plus Camrelizumab in Soft Tissue Sarcoma
NCT05189483Phase 2Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Jan 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and paclitaxel in soft tissue sarcoma (STS), sponsored by Henan Cancer Hospital. Primary endpoint: Progression-Free Survival at 24 months. Status: unknown.
02
Drugs
camrelizumabpaclitaxel
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT05189483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05189483.